Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.

Chatterjee D, Rashid A, Wang H, Katz MH, Wolff RA, Varadhachary GR, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Am J Surg Pathol. 2012 Apr;36(4):552-9. doi: 10.1097/PAS.0b013e318240c1c0.

2.

Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.

Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Am J Surg Pathol. 2012 Mar;36(3):409-17. doi: 10.1097/PAS.0b013e31824104c5.

3.

Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H.

Cancer. 2012 Jan 1;118(1):268-77. doi: 10.1002/cncr.26243. Epub 2011 Jul 6.

4.

Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.

Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H.

Am J Surg Pathol. 2017 Aug;41(8):1097-1104. doi: 10.1097/PAS.0000000000000887.

PMID:
28614206
5.

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB.

Ann Surg Oncol. 2015 Apr;22(4):1168-75. doi: 10.1245/s10434-014-4192-6. Epub 2014 Oct 29.

6.

Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer. 2012 Jun 15;118(12):3182-90. doi: 10.1002/cncr.26651. Epub 2011 Oct 25.

7.

Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.

Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H.

Am J Surg Pathol. 2016 Dec;40(12):1653-1660.

8.

Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Jamieson NB, Foulis AK, Oien KA, Dickson EJ, Imrie CW, Carter R, McKay CJ.

J Gastrointest Surg. 2011 Mar;15(3):512-24. doi: 10.1007/s11605-010-1395-4. Epub 2010 Nov 30.

PMID:
21116727
9.

Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.

Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Ann Diagn Pathol. 2012 Jan;16(1):29-37. doi: 10.1016/j.anndiagpath.2011.08.005. Epub 2011 Nov 3.

10.

Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?

Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, Bassi C, Pederzoli P, Falconi M.

Surgery. 2012 Sep;152(3 Suppl 1):S112-9. doi: 10.1016/j.surg.2012.05.017. Epub 2012 Jul 3.

PMID:
22766365
11.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.

PMID:
25445504
12.

Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium.

Ethun CG, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Idrees K, Fields RC, Weber SM, Cho C, Martin RC, Scoggins CR, Shen P, Schmidt C, Hatzaras I, Bentrem D, Ahmad S, Abbott D, Kim HJ, Merchant N, Staley CA, Kooby DA, Maithel SK.

J Am Coll Surg. 2017 Apr;224(4):406-413. doi: 10.1016/j.jamcollsurg.2016.12.006. Epub 2016 Dec 23.

PMID:
28017812
13.

Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion.

Chen JW, Bhandari M, Astill DS, Wilson TG, Kow L, Brooke-Smith M, Toouli J, Padbury RT.

HPB (Oxford). 2010 Mar;12(2):101-8. doi: 10.1111/j.1477-2574.2009.00140.x.

14.

Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).

Duconseil P, Périnel J, Autret A, Adham M, Sauvanet A, Chiche L, Mabrut JY, Tuech JJ, Mariette C, Régenet N, Fabre JM, Bachellier P, Delpéro JR, Paye F, Turrini O.

Eur J Surg Oncol. 2017 Sep;43(9):1704-1710. doi: 10.1016/j.ejso.2017.06.011. Epub 2017 Jun 29.

PMID:
28687431
15.
16.

Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma.

Epstein JD, Kozak G, Fong ZV, He J, Javed AA, Joneja U, Jiang W, Ferrone CR, Lillemoe KD, Cameron JL, Weiss MJ, Lavu H, Yeo CJ, Fernandez-Del Castillo C, Wolfgang CL, Winter JM.

J Surg Oncol. 2017 Nov;116(6):658-664. doi: 10.1002/jso.24723. Epub 2017 Jun 19.

PMID:
28628722
18.

Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.

Chen WH, Huang YL, Chao YK, Yeh CJ, Chang HK, Tseng CK, Liu YH.

Ann Surg Oncol. 2015 Jan;22(1):338-43. doi: 10.1245/s10434-014-3881-5. Epub 2014 Jul 15.

PMID:
25023545
19.

Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H.

Histopathology. 2013 Dec;63(6):841-51. doi: 10.1111/his.12234. Epub 2013 Sep 20.

20.

[A result of surgical treatment for ductal adenocarcinoma of the head of the pancreas].

Moon HJ, Jang KT, Heo JS, Choi SH, Joh JW, Kim YI.

Korean J Gastroenterol. 2003 Aug;42(2):156-63. Korean.

Supplemental Content

Support Center